PositiveID and GenArraytion Partner on Firefly Dx

DELRAY BEACH, Fla., Aug. 04, 2015 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a developer of biological detection and diagnostics solutions, and GenArraytion Inc., a developer of real-time multiplex PCR (polymerase chain reaction) assays, today announced that they have entered into an agreement to partner and evaluate GenArraytion’s assays on PositiveID’s Firefly Dx PCR breadboard prototype pathogen detection system (“prototype system”).
Firefly Dx is designed to provide real-time, accurate diagnostic results in a handheld device, thereby leading to treatment scenarios at the point of need that are not possible with existing systems, which require lab-based equipment and can take hours or even days to provide results. Firefly’s applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.
GenArraytion’s MultiFLEX Bioassays™ for clinically relevant pathogens and bio-threat agents provide a significant advance in multiplexing flexibility, with up to 20 DNA and/or RNA targets in a single assay panel that can be mixed and matched.  They are readily configurable, highly specific and sensitive multiplex PCR assays ready for use in real-time and bead-based end-point platforms. MultiFLEX Bioassays™ are developed for clinical pathogens and veterinary disease agents as well as food or water-borne pathogens and biological threats.
Dr. R. Paul Schaudies, CEO of GenArraytion, stated, “We are very interested in the work PositiveID is doing with its Firefly Dx, which could significantly advance the capabilities of the real-time PCR market, and we are pleased to partner with them to test our assays on this exciting and essential point-of-need technology platform.”
“GenArraytion’s competencies and real-time PCR assays are first-rate, which is evidenced by their world-class customer base, and we believe our cooperative experience will provide us an opportunity to further advance the development and testing of Firefly Dx,” said Lyle Probst, President of PositiveID.

Sourced through Scoop.it from: money.cnn.com

See on Scoop.itBiodefense News

Leave a Reply